Skip to main content
Reimbursement strategy

Cost-effective market access strategy for medical technologies in Europe

A holistic approach to reimbursement strategies trusted by global market leaders and SMEs

Learn more
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

Approval of uniform financing of outpatient and inpatient care in Switzerland

In December 2023, the Swiss parliament adopted the uniform financing of outpatient and inpatient services (einheitliche Finanzierung ambulanter und stationärer Leistungen, EFAS). Currently, inpatient benefits are financed jointly by health insurers and the cantons. Outpatient services, however, are entirely funded by the insured through premiums. With the implementation of the EFAS reform, inpatient and outpatient services will be financed in a uniform way.

The EFAS will come into force on January 1, 2028, with healthcare services being integrated into this system four years later.

See the full details here.

This news is just one of about 300 market access news collected by our team in the premium subscription service Market Access Monitor every week from more than 80 organizations. Access our paid service to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Access is organized as an online Database and email alert formats. Contact us to get a free, three-month, no-obligation trial.